Skip to content
Open menu Close menu

Professor Chris Twelves

PositionClinical Director and Professor of Clinical Cancer Pharmacology and Oncology
DepartmentInstitute of Cancer Therapeutics
Telephone+44 (0) 113 206 8186
EmailC.J.Twelves@leeds.ac.uk

Administrative Responsibilities


 

Professional Activities

  • Past Chairman of the New Drug Development Group of the EORTC.
  • Feasibility Studies Committee Cancer Research UK
  • New Agents Committee Cancer Research UK
  • Phase I/II Committee Cancer Research UK
  • ASCO Foundation Grants Committee

Research Areas

  • Early drug development and the pharmacology of anticancer drugs.
  • Clinical practice in breast and colorectal cancer

Networks/Roles

  • Leadership of translational research
  • Developing links within the Leeds Cancer Research UK Clinical Centre
  • Supervising and monitoring of clinicians undertaking PhD Projects

Publications

  • Twelves C. Trials and tribulations of cytotoxic and targeted breast cancer therapy: a clinical perspective on the next phase of progress. Expert Rev Anticancer Ther. 2013 Mar;13(3):251-5. doi: 10.1586/era.13.3. PubMed PMID: 23477510
  • Seligmann J, Twelves C. Tubulin: an example of targeted chemotherapy. Future Med Chem. 2013 Mar;5(3):339-52. doi: 10.4155/fmc.12.217. PubMed PMID: 23464522
  • Anthoney DA, Naik J, Macpherson IR, Crawford D, Hartley JM, Hartley JA, Saito T, Abe M, Jones K, Miwa M, Twelves C, Evans TR. Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses. BMC Cancer. 2012 Nov 21;12:536. doi: 10.1186/1471-2407-12-536. PubMed PMID: 23170896; PubMed Central PMCID: PMC3517777
  • Twelves C, Scheithauer W, McKendrick J, Seitz JF, Van Hazel G, Wong A, Díaz-Rubio E, Gilberg F, Cassidy J. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol. 2012 May;23(5):1190-7. doi: 10.1093/annonc/mdr366. Epub 2011 Sep 6. PubMed PMID: 21896539
  • Naik JD, Twelves CJ, Selby PJ, Vile RG, Chester JD. Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy? Clin Cancer Res. 2011 Jul 1;17(13):4214-24. doi: 10.1158/1078-0432.CCR-10-2848. Epub 2011 May 16. PubMed PMID: 21576084; PubMed Central PMCID: PMC3131422
  • Twelves C, Vahdat LT, Cortés J. Novel treatment options in the management of metastatic breast cancer. Clin Adv Hematol Oncol. 2011 May;9(5 Suppl 10):1-16. PubMed PMID: 21738118
  • Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011 Mar 12;377(9769):914-23. doi: 10.1016/S0140-6736(11)60070-6. Epub 2011 Mar 2. PubMed PMID: 21376385
  • Twelves C, Cortes J, Vahdat LT, Wanders J, Akerele C, Kaufman PA. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin Breast Cancer. 2010 Apr;10(2):160-3. doi: 10.3816/CBC.2010.n.023. PubMed PMID: 20299316

Share this